Claudia Waskow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claudia Waskow has a total of 928 co-authors. Here are the top co-authors by number of shared publications:
Susann Rahmig
Immunology of Aging, Leibniz Institute on Aging – Fritz Lipmann Institute, Jena, Germany
10 shared publications- Amit Gutwillig
Nucleai, Tel Aviv 6744840, Israel
9 shared publications - Diana Rasoulouniriana
Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
9 shared publications - Hana Shpilt
Gilboa Therapeutics Ltd., Rehovot, Israel
9 shared publications - Leen Farhat-Younis
Department of Pathology, School of Medicine, Tel Aviv University
9 shared publications - Lior Tal
Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
9 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in Angewandte Chemie International Edition
Comparative Analysis of Poly(Ethylene Glycol) (PEG) and Poly(2‐Ethyl‐2‐Oxazoline) (PEtOx) for Organic Solvent‐Free Lipid Nanoparticle Formulations
Efficient, biocompatible, and flexible application of CRISPR‐Cas9 remains a major challenge in gene therapy. This study addresses a novel formulation method, focusing on organic solvent‐free lipid nanoparticles for the efficient delivery of CRISPR‐Cas9 components. Therefore, novel stealth lipids comprising the lipid anchor cholesterol hemisuccinate conjugated to poly(2‐ethyl‐2‐oxazoline) (PEtOx) were synthesized and evaluated as a promising in vitro alternative to commercially available poly(ethylene glycol) (PEG)‐based lipids. Our study identified PEtOx‐lipids as markedly more biocompatible compared to PEG‐based analogues (12‐fold reduction in cytotoxicity; 99% reduced hemolytic effect) with high efficiency for mRNA gene delivery. We demonstrate successful CRISPR‐Cas9 activity ex vivo and efficient uptake of PEtOx nanoparticles by macrophages in vivo (66.5% pos. F4/80 + macrophages). Our data demonstrate that PEtOx‐based stealth lipids are a promising alternative to PEG. The resulting LNPs, optimized for fully aqueous manufacturing, address key limitations of current LNP systems, including immunogenicity and the reliance on ethanol‐based production processes.
- 27 October 2026
- Published by Wiley in Angewandte Chemie International Edition
Open AccessComparative Analysis of Poly(Ethylene Glycol) (PEG) and Poly(2‐Ethyl‐2‐Oxazoline) (PEtOx) for Organic Solvent‐Free Lipid Nanoparticle Formulations
Efficient, biocompatible, and flexible application of CRISPR‐Cas9 remains a major challenge in gene therapy. This study addresses a novel formulation method, focusing on organic solvent‐free lipid nanoparticles for the efficient delivery of CRISPR‐Cas9 components. Therefore, novel stealth lipids comprising the lipid anchor cholesterol hemisuccinate conjugated to poly(2‐ethyl‐2‐oxazoline) (PEtOx) were synthesized and evaluated as a promising in vitro alternative to commercially available poly(ethylene glycol) (PEG)‐based lipids. Our study identified PEtOx‐lipids as markedly more biocompatible compared to PEG‐based analogues (12‐fold reduction in cytotoxicity; 99% reduced hemolytic effect) with high efficiency for mRNA gene delivery. We demonstrate successful CRISPR‐Cas9 activity ex vivo and efficient uptake of PEtOx nanoparticles by macrophages in vivo (66.5% pos. F4/80 + macrophages). Our data demonstrate that PEtOx‐based stealth lipids are a promising alternative to PEG. The resulting LNPs, optimized for fully aqueous manufacturing, address key limitations of current LNP systems, including immunogenicity and the reliance on ethanol‐based production processes.
- Open Access
- 27 October 2026
- Published by Wiley in Angewandte Chemie
Vergleich von Polyethylenglykol (PEG) und Poly(2‐ethyl‐2‐oxazolin) (PEtOx) für die lösungsmittelfreie Formulierung von Lipidnanopartikeln
ZUSAMMENFASSUNG: Eine effiziente, biokompatible und flexible Anwendung von CRISPR‐Cas9 stellt weiterhin eine wesentliche Herausforderung in der Gentherapie dar. Die vorliegende Studie untersucht eine neuartige Formulierungsmethode mit Fokus auf lösungsmittelfreien Lipidnanopartikeln zur effizienten Verabreichung von CRISPR‐Cas9‐Komponenten. Hierzu wurden neuartige Stealth‐Lipide synthetisiert, die auf dem Lipidanker Cholesterinhemisuccinat basieren und mit Poly(2‐ethyl‐2‐oxazolin) (PEtOx) konjugiert wurden. Diese stellen in vitro eine vielversprechende Alternative zu kommerziell verfügbaren Lipiden auf Basis von Polyethylenglykol (PEG) dar. Unsere Studie identifizierte PEtOx‐Lipide als deutlich biokompatibler im Vergleich zu PEG‐basierten Analoga, mit einer 12‐fachen Reduktion der Zytotoxizität und einer um 99 % reduzierten hämolytischen Wirkung bei gleichzeitig hoher Effizienz für den mRNA Gentransfer. Darüber hinaus konnten wir eine erfolgreiche CRISPR‐Cas9‐Aktivität ex vivo sowie eine effiziente Aufnahme von PEtOx‐Nanopartikeln durch Makrophagen in vivo nachweisen (66,5 % F4/80 + ‐Makrophagen). Unsere Daten zeigen, dass PEtOx‐basierte Stealth‐Lipide eine vielversprechende Alternative zu PEG darstellen. Die resultierenden LNPs, die für eine vollständig wässrige Herstellung optimiert wurden, adressieren zentrale Limitationen bestehender LNP‐Systeme, darunter die Immunogenität und die Abhängigkeit von ethanolbasierten Herstellungsverfahren.
- 27 October 2026
- Published by Wiley in Angewandte Chemie
Open AccessVergleich von Polyethylenglykol (PEG) und Poly(2‐ethyl‐2‐oxazolin) (PEtOx) für die lösungsmittelfreie Formulierung von Lipidnanopartikeln
ZUSAMMENFASSUNG: Eine effiziente, biokompatible und flexible Anwendung von CRISPR‐Cas9 stellt weiterhin eine wesentliche Herausforderung in der Gentherapie dar. Die vorliegende Studie untersucht eine neuartige Formulierungsmethode mit Fokus auf lösungsmittelfreien Lipidnanopartikeln zur effizienten Verabreichung von CRISPR‐Cas9‐Komponenten. Hierzu wurden neuartige Stealth‐Lipide synthetisiert, die auf dem Lipidanker Cholesterinhemisuccinat basieren und mit Poly(2‐ethyl‐2‐oxazolin) (PEtOx) konjugiert wurden. Diese stellen in vitro eine vielversprechende Alternative zu kommerziell verfügbaren Lipiden auf Basis von Polyethylenglykol (PEG) dar. Unsere Studie identifizierte PEtOx‐Lipide als deutlich biokompatibler im Vergleich zu PEG‐basierten Analoga, mit einer 12‐fachen Reduktion der Zytotoxizität und einer um 99 % reduzierten hämolytischen Wirkung bei gleichzeitig hoher Effizienz für den mRNA Gentransfer. Darüber hinaus konnten wir eine erfolgreiche CRISPR‐Cas9‐Aktivität ex vivo sowie eine effiziente Aufnahme von PEtOx‐Nanopartikeln durch Makrophagen in vivo nachweisen (66,5 % F4/80 + ‐Makrophagen). Unsere Daten zeigen, dass PEtOx‐basierte Stealth‐Lipide eine vielversprechende Alternative zu PEG darstellen. Die resultierenden LNPs, die für eine vollständig wässrige Herstellung optimiert wurden, adressieren zentrale Limitationen bestehender LNP‐Systeme, darunter die Immunogenität und die Abhängigkeit von ethanolbasierten Herstellungsverfahren.
- Open Access
Leukemic Stem Cell Subtypes Drive Distinct Niche Remodeling in Acute Myeloid Leukemia
Leukemic stem cells (LSCs) sustain acute myeloid leukemia (AML) and are implicated in therapy resistance and relapse. Yet, it remains unknown how LSCs remodel the bone marrow niche. AML is known to alter stromal and vascular microenvironments, but these effects are difficult to separate from bulk leukemic burden and immune inflammation. Here, we use isogenic human AML xenografts with distinct LSC characteristics but comparable engraftment to define LSC-associated niche remodeling in vivo. Single-cell profiling revealed that LSC-high AML shifts the mesenchymal niche toward fibro-inflammatory states, expanding Fmod+ fibroblasts and Cd34+ perivascular fibroblast-like cells while suppressing osteolineage differentiation. The leukemic compartment remained heterogeneous, with a specific MEP-like LSC population expressing niche-remodeling ligands including TGFB1, IL1B, and ANGPT1. LSC-high AML activated a TGFβ-responsive, CREB3L1-controlled fibroblast trajectory, and perturbing TGFβ signaling or CREB3L1 activation reduced stromal support for AML cells. These findings identify a specific LSC subtype as a source of niche-remodeling cues that shape specialized leukemia-supportive niches.
Open AccessLeukemic Stem Cell Subtypes Drive Distinct Niche Remodeling in Acute Myeloid Leukemia
Leukemic stem cells (LSCs) sustain acute myeloid leukemia (AML) and are implicated in therapy resistance and relapse. Yet, it remains unknown how LSCs remodel the bone marrow niche. AML is known to alter stromal and vascular microenvironments, but these effects are difficult to separate from bulk leukemic burden and immune inflammation. Here, we use isogenic human AML xenografts with distinct LSC characteristics but comparable engraftment to define LSC-associated niche remodeling in vivo. Single-cell profiling revealed that LSC-high AML shifts the mesenchymal niche toward fibro-inflammatory states, expanding Fmod+ fibroblasts and Cd34+ perivascular fibroblast-like cells while suppressing osteolineage differentiation. The leukemic compartment remained heterogeneous, with a specific MEP-like LSC population expressing niche-remodeling ligands including TGFB1, IL1B, and ANGPT1. LSC-high AML activated a TGFβ-responsive, CREB3L1-controlled fibroblast trajectory, and perturbing TGFβ signaling or CREB3L1 activation reduced stromal support for AML cells. These findings identify a specific LSC subtype as a source of niche-remodeling cues that shape specialized leukemia-supportive niches.
- Open Access
Deploying cross-species bone marrow niches to elucidate human hematopoietic stem cell regulation in vivo
The regulation of human hematopoietic stem cell (HSC) function within its native bone marrow microenvironment remains poorly understood due to the limitations of existing humanized models. Here, we present a non-conditioned human HSC xenotransplantation platform that serves as a physiologically relevant in vivo surrogate to study these complex cellular interactions. Using this system, we uncover a dynamic, cross-species communication between human HSCs and the murine niche, revealing a profound cellular and molecular plasticity of the bone marrow microenvironment in response to humanization. Upon engraftment, platelet-derived growth factor receptor alpha positive (Pdgfra + ) mesenchymal stromal cells (MSCs) undergo significant numerical expansion and a major transcriptional shift, transitioning from a mixed adipo- and osteo-primed state toward a leptin receptor positive (Lepr + ) predominantly adipo-primed, hematopoiesis-supporting signature. Functional validation demonstrates that this niche plasticity is a critical determinant of stem cell engraftment: the targeted depletion of Lepr + MSCs or the genetic deletion of stem cell factor results in the rapid mobilization and lack of engraftment of human HSCs, respectively. Our findings establish niche plasticity as a primary regulator of human HSC function and demonstrate the utility of this cross-species platform as a modular genetic toolbox for precise in vivo engineering of the bone marrow microenvironment. Ultimately, this adaptable system provides a powerful framework for elucidating human stem cell biology and advancing bone marrow transplantation therapies.
Open AccessDeploying cross-species bone marrow niches to elucidate human hematopoietic stem cell regulation in vivo
The regulation of human hematopoietic stem cell (HSC) function within its native bone marrow microenvironment remains poorly understood due to the limitations of existing humanized models. Here, we present a non-conditioned human HSC xenotransplantation platform that serves as a physiologically relevant in vivo surrogate to study these complex cellular interactions. Using this system, we uncover a dynamic, cross-species communication between human HSCs and the murine niche, revealing a profound cellular and molecular plasticity of the bone marrow microenvironment in response to humanization. Upon engraftment, platelet-derived growth factor receptor alpha positive (Pdgfra + ) mesenchymal stromal cells (MSCs) undergo significant numerical expansion and a major transcriptional shift, transitioning from a mixed adipo- and osteo-primed state toward a leptin receptor positive (Lepr + ) predominantly adipo-primed, hematopoiesis-supporting signature. Functional validation demonstrates that this niche plasticity is a critical determinant of stem cell engraftment: the targeted depletion of Lepr + MSCs or the genetic deletion of stem cell factor results in the rapid mobilization and lack of engraftment of human HSCs, respectively. Our findings establish niche plasticity as a primary regulator of human HSC function and demonstrate the utility of this cross-species platform as a modular genetic toolbox for precise in vivo engineering of the bone marrow microenvironment. Ultimately, this adaptable system provides a powerful framework for elucidating human stem cell biology and advancing bone marrow transplantation therapies.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
Supplementary tables and figures
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
Supplementary tables and figures
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
The pioneering design of chimeric antigen receptor (CAR) T-cell therapy demonstrated the potential of reprogramming the immune system. Nonetheless, T-cell exhaustion, toxicity, and suppressive microenvironments limit their efficacy in solid tumors. We previously characterized a subset of tumor-infiltrating CD4+ T cells expressing the FcγRI receptor. Herein, we detail engineering of a receptor, based on the FcγRI structure, allowing T cells to target tumor cells using antibody intermediates. These T cells showed effective and specific cytotoxicity only when an appropriate antibody was added. Only target-bound antibodies activated these cells, while free antibodies were internalized without activation. Their cytotoxic activity was correlated to target protein density, therefore targeting tumor cells with high antigen density while sparing normal cells with low or no expression. This activation mechanism prevented premature exhaustion. Furthermore, during antibody-dependent cytotoxicity these cells secreted attenuated cytokine levels compared with CAR T cells, thereby enhancing their safety profile. These cells eradicated established melanomas, infiltrated the tumor microenvironment, and facilitated host immune cell recruitment in immunocompetent mice. In NOD/SCID gamma mice the cells infiltrate, persist, and eradicate tumors. As opposed to CAR T-cell therapies, which require changing the receptor across different types of cancer, our engineered T cells remain the same across tumor types, while only the injected antibody changes. Overall, we generated a highly flexible T-cell therapy capable of binding a wide range of tumor cells with high affinity, while preserving the cytotoxic specificity only to cells expressing high density of tumor-associated antigens and using a single manufacturing process.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
The pioneering design of chimeric antigen receptor (CAR) T-cell therapy demonstrated the potential of reprogramming the immune system. Nonetheless, T-cell exhaustion, toxicity, and suppressive microenvironments limit their efficacy in solid tumors. We previously characterized a subset of tumor-infiltrating CD4+ T cells expressing the FcγRI receptor. Herein, we detail engineering of a receptor, based on the FcγRI structure, allowing T cells to target tumor cells using antibody intermediates. These T cells showed effective and specific cytotoxicity only when an appropriate antibody was added. Only target-bound antibodies activated these cells, while free antibodies were internalized without activation. Their cytotoxic activity was correlated to target protein density, therefore targeting tumor cells with high antigen density while sparing normal cells with low or no expression. This activation mechanism prevented premature exhaustion. Furthermore, during antibody-dependent cytotoxicity these cells secreted attenuated cytokine levels compared with CAR T cells, thereby enhancing their safety profile. These cells eradicated established melanomas, infiltrated the tumor microenvironment, and facilitated host immune cell recruitment in immunocompetent mice. In NOD/SCID gamma mice the cells infiltrate, persist, and eradicate tumors. As opposed to CAR T-cell therapies, which require changing the receptor across different types of cancer, our engineered T cells remain the same across tumor types, while only the injected antibody changes. Overall, we generated a highly flexible T-cell therapy capable of binding a wide range of tumor cells with high affinity, while preserving the cytotoxic specificity only to cells expressing high density of tumor-associated antigens and using a single manufacturing process.
- Open Access
- 14 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Embryonic macrophages orchestrate niche cell homeostasis for the establishment of the definitive hematopoietic stem cell pool
Embryonic macrophages emerge before the onset of definitive hematopoiesis, seed into discrete tissues and contribute to specialized resident macrophages throughout life. Presence of embryonic macrophages in the bone marrow and functional impact on hematopoietic stem cells (HSC) or the niche remains unclear. Here we show that bone marrow macrophages consist of two ontogenetically distinct cell populations from embryonic and adult origin. Newborn mice lacking embryonic macrophages have decreased HSC numbers in the bone marrow suggesting an important function for embryo-derived macrophages in orchestrating HSC trafficking around birth. The establishment of a normal cellular niche space in the bone marrow critically depends on embryonic macrophages that are important for the development of mesenchymal stromal cells, but not other non-hematopoietic niche cells, providing evidence for a specific role for embryo-derived macrophages in the establishment of the niche environment pivotal for the establishment of a normally sized HSC pool.
- 14 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessEmbryonic macrophages orchestrate niche cell homeostasis for the establishment of the definitive hematopoietic stem cell pool
Embryonic macrophages emerge before the onset of definitive hematopoiesis, seed into discrete tissues and contribute to specialized resident macrophages throughout life. Presence of embryonic macrophages in the bone marrow and functional impact on hematopoietic stem cells (HSC) or the niche remains unclear. Here we show that bone marrow macrophages consist of two ontogenetically distinct cell populations from embryonic and adult origin. Newborn mice lacking embryonic macrophages have decreased HSC numbers in the bone marrow suggesting an important function for embryo-derived macrophages in orchestrating HSC trafficking around birth. The establishment of a normal cellular niche space in the bone marrow critically depends on embryonic macrophages that are important for the development of mesenchymal stromal cells, but not other non-hematopoietic niche cells, providing evidence for a specific role for embryo-derived macrophages in the establishment of the niche environment pivotal for the establishment of a normally sized HSC pool.
- Open Access
- 4 March 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Resident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia
Cardiac macrophages are heterogenous in phenotype and functions, which has been associated with differences in their ontogeny. Despite extensive research, our understanding of the precise role of different subsets of macrophages in ischemia/reperfusion injury remains incomplete. We here investigated macrophage lineages and ablated tissue macrophages in homeostasis and after I/R injury in a CSF1R-dependent manner. Genomic deletion of a fms-intronic regulatory element (FIRE) in the Csf1r locus resulted in specific absence of resident homeostatic and antigen-presenting macrophages, without affecting the recruitment of monocyte-derived macrophages to the infarcted heart. Specific absence of homeostatic, monocyte-independent macrophages altered the immune cell crosstalk in response to injury and induced proinflammatory neutrophil polarization, resulting in impaired cardiac remodelling without influencing infarct size. In contrast, continuous CSF1R inhibition led to depletion of both resident and recruited macrophage populations. This augmented adverse remodelling after I/R and led to an increased infarct size and deterioration of cardiac function. In summary, resident macrophages orchestrate inflammatory responses improving cardiac remodelling, while recruited macrophages determine infarct size after I/R injury. These findings attribute distinct beneficial effects to different macrophage populations in the context of myocardial infarction.
- 4 March 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessResident and recruited macrophages differentially contribute to cardiac healing after myocardial ischemia
Cardiac macrophages are heterogenous in phenotype and functions, which has been associated with differences in their ontogeny. Despite extensive research, our understanding of the precise role of different subsets of macrophages in ischemia/reperfusion injury remains incomplete. We here investigated macrophage lineages and ablated tissue macrophages in homeostasis and after I/R injury in a CSF1R-dependent manner. Genomic deletion of a fms-intronic regulatory element (FIRE) in the Csf1r locus resulted in specific absence of resident homeostatic and antigen-presenting macrophages, without affecting the recruitment of monocyte-derived macrophages to the infarcted heart. Specific absence of homeostatic, monocyte-independent macrophages altered the immune cell crosstalk in response to injury and induced proinflammatory neutrophil polarization, resulting in impaired cardiac remodelling without influencing infarct size. In contrast, continuous CSF1R inhibition led to depletion of both resident and recruited macrophage populations. This augmented adverse remodelling after I/R and led to an increased infarct size and deterioration of cardiac function. In summary, resident macrophages orchestrate inflammatory responses improving cardiac remodelling, while recruited macrophages determine infarct size after I/R injury. These findings attribute distinct beneficial effects to different macrophage populations in the context of myocardial infarction.
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
Supplementary tables and figures
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
Supplementary tables and figures
- Open Access
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Data from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
The pioneering design of chimeric antigen receptor (CAR) T-cell therapy demonstrated the potential of reprogramming the immune system. Nonetheless, T-cell exhaustion, toxicity, and suppressive microenvironments limit their efficacy in solid tumors. We previously characterized a subset of tumor-infiltrating CD4+ T cells expressing the FcγRI receptor. Herein, we detail engineering of a receptor, based on the FcγRI structure, allowing T cells to target tumor cells using antibody intermediates. These T cells showed effective and specific cytotoxicity only when an appropriate antibody was added. Only target-bound antibodies activated these cells, while free antibodies were internalized without activation. Their cytotoxic activity was correlated to target protein density, therefore targeting tumor cells with high antigen density while sparing normal cells with low or no expression. This activation mechanism prevented premature exhaustion. Furthermore, during antibody-dependent cytotoxicity these cells secreted attenuated cytokine levels compared with CAR T cells, thereby enhancing their safety profile. These cells eradicated established melanomas, infiltrated the tumor microenvironment, and facilitated host immune cell recruitment in immunocompetent mice. In NOD/SCID gamma mice the cells infiltrate, persist, and eradicate tumors. As opposed to CAR T-cell therapies, which require changing the receptor across different types of cancer, our engineered T cells remain the same across tumor types, while only the injected antibody changes. Overall, we generated a highly flexible T-cell therapy capable of binding a wide range of tumor cells with high affinity, while preserving the cytotoxic specificity only to cells expressing high density of tumor-associated antigens and using a single manufacturing process.
- 2 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
The pioneering design of chimeric antigen receptor (CAR) T-cell therapy demonstrated the potential of reprogramming the immune system. Nonetheless, T-cell exhaustion, toxicity, and suppressive microenvironments limit their efficacy in solid tumors. We previously characterized a subset of tumor-infiltrating CD4+ T cells expressing the FcγRI receptor. Herein, we detail engineering of a receptor, based on the FcγRI structure, allowing T cells to target tumor cells using antibody intermediates. These T cells showed effective and specific cytotoxicity only when an appropriate antibody was added. Only target-bound antibodies activated these cells, while free antibodies were internalized without activation. Their cytotoxic activity was correlated to target protein density, therefore targeting tumor cells with high antigen density while sparing normal cells with low or no expression. This activation mechanism prevented premature exhaustion. Furthermore, during antibody-dependent cytotoxicity these cells secreted attenuated cytokine levels compared with CAR T cells, thereby enhancing their safety profile. These cells eradicated established melanomas, infiltrated the tumor microenvironment, and facilitated host immune cell recruitment in immunocompetent mice. In NOD/SCID gamma mice the cells infiltrate, persist, and eradicate tumors. As opposed to CAR T-cell therapies, which require changing the receptor across different types of cancer, our engineered T cells remain the same across tumor types, while only the injected antibody changes. Overall, we generated a highly flexible T-cell therapy capable of binding a wide range of tumor cells with high affinity, while preserving the cytotoxic specificity only to cells expressing high density of tumor-associated antigens and using a single manufacturing process.